科创板第五套标准重启后首家，泰诺麦博IPO获受理

Core Viewpoint - Zhuhai Tainuo Maibo Pharmaceutical Co., Ltd. has been accepted for IPO on the Sci-Tech Innovation Board, marking it as the first company to be accepted under the newly restarted fifth listing standard [1][10] Company Overview - Established in 2015, Tainuo Maibo focuses on the research, production, and sales of fully human monoclonal antibody drugs [2][3] - The company utilizes its proprietary high-throughput fully human monoclonal antibody research platform, HitmAb®, to develop safer and more effective antibody drugs [2] Key Products - The core product, Staitouta Monoclonal Antibody Injection, is the first-in-class recombinant monoclonal antibody drug for tetanus toxin, approved for sale in China in February 2025 [2][4] - Another key product, TNM001, is a long-acting monoclonal antibody for RSV prevention, currently undergoing Phase III clinical trials [2][4] Financial Performance - Tainuo Maibo has not yet achieved profitability, thus opting for the fifth listing standard, which requires a projected market value of no less than RMB 4 billion [3] - The company reported a revenue of RMB 16.93 million from drug sales in Q1 2025, following the launch of its core product [4][5] Research and Development - R&D expenditures from 2022 to Q1 2025 were RMB 323 million, RMB 393 million, RMB 425 million, and RMB 134 million, with a compound annual growth rate of 14.80% [6][7] - The company plans to accelerate the commercialization of its products and expand its pipeline, including advancing clinical trials for TNM009, TNM005, TNM006, and TNM035 [8] Shareholding Structure - Tainuo Maibo has no controlling shareholder, with actual control held by Huaxin Liao and Zheng Weihong, who collectively control 33.10% of the company [9][10] - The company has attracted investments from various institutional and foreign shareholders, including Zhuhai Hillhouse and several state-owned enterprises [10]